|
|
|
Annual Information Service
The Outlook for Pharmaceuticals in Central Asia
|
The Outlook for Pharmaceuticals in Central Asia published by Espicom Business Intelligence. This annual information service price starts from US $ 3630.
Abstract
Description
These reports provide a detailed analysis of four of the most populous countries in the world and the massive potential of their pharmaceutical markets. The markets of Central Asia contrast well; China and India are two of the largest pharmaceutical markets with very large economies, whilst Bangladesh and Pakistan are two of the smallest pharmaceutical markets with significantly smaller economies.
Bangladesh, China, India and Pakistan are projected to have a combined population of 3.0 billion in 2016, which will represent 79.1% of the total population of the Asia Pacific region covered by Espicom. As a percentage of the population, these four countries will have small elderly populations. However, they are projected to account for 72.4% of the total elderly population in the Asia Pacific region in 2016.
China and India are projected to have the largest and third largest GDPs in the region in 2016, respectively. Both are part of the BRICS group that represents the world's largest emerging economies, along with Brazil, Russia and South Africa. The BRICS countries are predicted to become the most dominant economies over the next few decades, which could lead to a shift in the global balance of economic power.
Bangladesh and Pakistan are projected to have the lowest and second lowest GDPs per capita in the Asia Pacific region in 2016, as these are two of the poorest countries in the world that also have large young populations. In comparison to China and India, the healthcare services of Bangladesh and Pakistan are underdeveloped, which is illustrated by limited health spending, low physician rates and high infant mortality rates.
Multinational pharmaceutical companies are increasingly looking to invest in or form partnerships in these four markets, due to the size of the potential drug consumer pool. The generic sectors in these four markets are particularly significant, and have grown rapidly in recent years. However, there still remain concerns over IP protection and its enforcement, which could deter multinational companies from entering these markets.
Highlights from the region
BANGLADESH
There is a large generic market in Bangladesh, and companies such as Square and Beximco are beginning to have success overseas. In November 2010, for instance, Beximco announced a strategic manufacturing, supply and product development agreement with the US firm, Adamis Pharmaceuticals, to launch generic drugs in the US market. However, despite the country possessing huge manufacturing capabilities which supply 96% of domestic need, the complete lack of R&D in domestic companies could affect the market, especially if companies have not evolved by the time the TRIPS agreement comes into effect.
CHINA
The Ministry of Health (MoH) has made lowering drug prices a top priority for health authorities in 2011. The National Development and Reform Commission (NDRC) implemented two rounds of drug price reductions in 2011, one in March and the other in September. Most of the drugs reduced were manufactured by multinationals, which had previously not been subject to pricing controls. In July 2011, the MoH revealed that it may introduce mandatory licensing policy to secure cheaper drugs for HIV/AIDS patients, as part of the country's universal health coverage programme. In January 2011, the MoH announced that the Essential Drugs List would be further expanded to cover nearly all government-sponsored grass-roots health institutions
INDIA
The Indian pharmaceutical industry is responsible for around 8% of world pharmaceutical production. Over the last couple of years, Indian pharmaceutical companies have been increasingly targeted by multinationals for both collaborative agreements and acquisition. During the first half of 2011, Bayer and Zydus Cadila agreed to set up a joint-venture called Bayer Zydus Pharma (BZP), for the sales and marketing of pharmaceutical products in India. BZP will operate in key segments of the Indian pharmaceutical market, with a focus on: women's healthcare, metabolic disorders, diagnostic imaging, cardiovascular diseases, diabetes treatments and oncology.
PAKISTAN
Pakistan's pharmaceutical market is small and equally split between multinational and domestic companies. Espicom projects the market to grow at a fairly high single-digit CAGR in dollar terms during the forecast period. By 2016, it will be the 11th largest pharmaceutical market in the Asia Pacific region covered by Espicom. The pharmaceutical market is dominated by locally manufactured pharmaceuticals, predominantly generic drugs, which meet around 90% of country's needs in 2011. Imported retail medicaments account for the remainder of the market, although manufacturers rely heavily on imported raw materials for production. Multinational companies account for around half of the market by value, although local producers have a far greater share in terms of volume.
Table of Contents
BANGLADESH
- PHARMACEUTICAL MARKET
- Current Size
- Projections
- Outlook
- Market Structure
- Imports
- Exports
- Research & Development
- Market Developments
- Drug Exports Set for Strong Growth
- HIV/AIDS Rates on the Rise in Bangladesh
- National Drug Policy
- International Projects
- ADB to Implement ‘High impact’ Health Services Package
- KEY NATIONAL DATA PROJECTIONS
List of Tables
- Summary of the Bangladesh Pharmaceutical Market, 2008
- Market Projections, 2008-2013
- SWOT Analysis of the Bangladesh Pharmaceutical Market
- Espicom Analysis of Bangladesh's Health Sector
- Domestic Pharmaceutical Production, 1989-1999
- Licensed Pharmaceutical Businesses by Categories, 1996-2004
- Imports by Category, 2002-2006 (US$000s)
- Import Trends, 2006 (US$000s)
- Leading Suppliers of Raw Materials, 2006 (US$000s)
- Leading Suppliers of Medicaments, 2006 (US$000s)
- Exports by Category, 2002-2006 (US$000s)
- Export Trends
- Leading Destinations, 2006 (US$000s)
List of Figures
- Radar Graph of the Bangladesh Healthcare System
- Domestic Pharmaceutical Production, 1989-1999 (US$ millions)
CHINA
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- 11th Five Year Plan Targets
- Local Manufacturers
- Aida Pharmaceuticals
- Anhui Anke Biotech
- Beijing Four Ring Biopharmaceutical Co. Ltd.
- Changzhou Siyao Pharmaceuticals Co. Ltd.
- China Pharmaceutical Enterprise
- China Sky One Medical
- Dragon Pharmaceuticals
- Fuzhou Antibiotic Group Corp
- Haizhou Pharmaceutical Co. Ltd.
- Harbin Pharmaceutical Group Co. Ltd.
- Heshuo Ephedrine Factory
- Huazhong Pharmaceutical Co. Ltd.
- Jiangsu Jiangan Pharmaceutical Corp Ltd.
- Jiuyuan
- Livzon (Group) Libao Biochemical & Pharmaceutical Co Ltd.
- Ningbo Jierfu Pharmaceutical Co Ltd.
- North China Pharmaceutical Huasheng Co. Ltd.
- Shenyang Sunshine Pharmaceutical Co Ltd.
- Shenzhen Kexing Biotech
- Shenzhen Zhijun Pharmaceutical Company
- Shenzhen Taitai Pharmaceutical Industry (Taitai)
- Sinovac Biotech Ltd.
- Wenzhou Pharmaceutical Factory
- Xiamen No.2 Pharmaceutical Factory
- Xinhua Pharma
- Yiyuan Pharmaceutical Co Ltd.
- Zhejiang Jinhua Lixin Fine Chemicals Co Ltd.
- Traditional Chinese Medicine
- Manufacturers
- China Conducts Research on Toxicity and Side Effects of TCM
- Multinational Manufacturers
- Allergan
- Antibioticos
- Astellas Pharma
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Eisai
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson
- Laboratories Servier
- Merck KGaA
- Merck Sharp & Dohme
- Novartis
- Novo Nordisk
- Pfizer
- Ranbaxy
- Rexim SA (Degussa)
- Roche
- Sanofi-Aventis
- Schering-Plough
- Takeda
- Mitsubishi Tanabe Pharma
- Watson
- Wyeth
- Exports
- Research & Development
- SFDA initiatives
- Zhangjiang Hi-Tech Park
- Beijing Union Pharmaceutical Factory
- Bayer
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Registration
- Revised Provisions for Drug Registration
- State Food and Drug Administration (SFDA)
- Department of Drug Registration
- Department of Drug Safety & Inspection
- Department of Drug Market Compliance
- Drug Classification
- Biotech regulation
- New Regulatory Legislation
- 2001 DAL Amendments
- The Drug Import Regulation
- GMP Regulations
- Pharmaceutical Registration/Drug Approval Process
- Clinical trials
- Quality test
- Certification
- Packaging Regulations
- Post-market Surveillance
- Licences of 160 drug firms revoked in 2006
- China Uncovers 1,001 Commercial Bribery Cases
- Pharmaceutical Advertising
- Patent Protection & Intellectual Property Rights
- Administrative Protection
- Pharmaceutical Pricing and Reimbursement
- Pricing
- Pricing Sector Developments
- Provincial governments
- Reimbursement Lists
- New Rule on Prescription of Drugs Effective May 2007
- Pharmaceutical Distribution
- Distribution System Reform
- Internet Pharmaceutical Distribution
- Pharmaceutical retail
- Shenzen Nepstar
- Distributors
- Chindex
- Hainan Kangtong Pharmaceutical Co Ltd.
- Huazhong Pharmaceutical Co. Ltd.
- Hunan Provincial Medicines & Health Products Import & Export Corp.
- Shandong Medicines & Health Products Import & Export Corp.
- Simcere Pharmaceutical Group
- Sincer Pharmchem Ltd.
- Sinochem Jiangsu Suzhou Import Export Corp.
- Tianjin Medicines & Health Products Import & Export Corp.
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- Incidence of Non-communicable Diseases
- HIV/AIDS
- Healthcare System
- US$124 Billion Healthcare Reform Plan
- Ministry of Health
- Hospitals
- Rural Healthcare
- Health Insurance
- Background
- Medical Insurance to Cover all Urban Citizens by 2010
- New Co-operative Medical Scheme (formerly Rural Co-operative Medical Scheme)
- Commercial Medical Insurance
- Red Cross Society of China
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Government Organisations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Chinese Pharmaceutical Market, 2009
- Market Projections, 2009-2014
- SWOT Analysis of the Chinese Pharmaceutical Market, 2009
- Espicom Analysis of China's Health Sector
- Imports of Pharmaceuticals by Category, 2003-2007 (US$000s)
- Import Trends
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- TCM Industrial Output Value (Billion Yuan) 2000-2007
- Dragon Pharmaceuticals Revenues by Segment, 2007 (US$ millions)
- Exports of Pharmaceuticals, 2003-07 (US$000s)
- Export Trends
- Leading Destinations, 2007 (US$000s)
- Nepstar Drugstores by City
- Summary of Demographic Data, 2006-07
- Projected Population, 2009-2014
- NCMS Funding and Expenditure 2005
- Healthcare Expenditure, 2006
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds, 2007
- Hospital Bed Projections, 2009-2014
- Admissions, 2002-2007 (millions)
- Hospital Admissions by Type 2005, (10,000s)
- Hospital Bed Utilisation Statistics, 1997-2007
- Projected Number of Physicians, 2009-2014 (000s)
INDIA
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Projections & Outlook
- Imports
- Raw Material Imports
- Finished Medicament Imports
- Domestic Manufacturing
- Domestic Production
- BCG Vaccine Laboratory, Chennai
- Trade Association(s)
- Local Manufacturers
- Alembic Ltd.
- Aurobindo Pharma
- Biocon
- Blue Cross Laboratories Ltd.
- Cipla Ltd.
- Claris Lifesciences
- Dr. Reddy's Laboratories Ltd.
- Glenmark Pharmaceuticals
- Jubilant Organosys
- Lupin Limited
- Matrix Laboratories
- Natco Pharma
- Orchid Chemicals & Pharmaceuticals Ltd.
- Piramal Healthcare
- Ranbaxy Laboratories Ltd.
- Strides Arcolab
- Sun Pharma
- Torrent Pharmaceuticals
- Wockhardt Ltd.
- Zydus Cadila
- Multinational Manufacturers
- Actavis
- GlaxoSmithKline
- Pfizer India
- sanofi-aventis
- Exports
- Research & Development
- Traditional Indian Medicines
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- National Pharmaceuticals Policy 2006
- Pharmaceutical Registration
- DGCI set to co-ordinate drug approvals
- Advertising
- Pricing
- Drugs (Prices Control) Amendment Order and Second Amendment Order, 2006
- Drug Price Control Review Committee
- Intellectual Property
- Background to Pharmaceutical Patents
- Mashelkar Committee Report, December 2006
- The Patents (Amendments) Bill, 2005
- Compulsory Licensing
- Pre- & Post-Grant Opposition
- Mailbox Applications
- Other Issues
- The Patents (Amendment) Rules 2006
- Previous Patents Act Amendments and Exclusive Marketing Rights
- Glivec/Gleevec Patent Setback for Novartis
- Pharmaceutical Distribution
- Medical Stores Organisation
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Communicable and Non-communicable Diseases
- National Rural Health Mission
- Child Survival and Safe Motherhood
- National Health Programmes for Disease Control/Eradication
- National Vector Borne Disease Control Programme
- Malaria
- Filariasis
- Kala-azar
- Japanese Encephalitis
- National Programme for the Control of Blindness
- National Leprosy Eradication Programme
- National Tuberculosis Control Programme
- HIV/AIDS
- National AIDS Control Programme
- National Programme for Prevention and Control of Diabetes, Cardiovascular Disease and Stroke
- Cancer
- Healthcare System
- Department of Health and Family Welfare
- The Department of AYUSH
- Health Insurance
- Apollo Family Health Plan
- Health Expenditure
- Healthcare Infrastructure
- All India Institute of Medical Sciences (AIIMS)
- Safdarjung Hospital, New Delhi
- Dr. Ram Manohar Lohia Hospital, New Delhi
- JIPMER Hospital, Pondicherry
- PGIMER Nehru Hospital, Chandigarh
- Lady Hardinge Medical College Associated Hospitals, New Delhi
- Tata Memorial Centre
- Private Hospitals and Clinics
- Apollo Hospitals Group
- Fortis Healthcare
- Max Healthcare
- Other Commercial Providers
- Primary Care
- First Aid and Disaster Relief
- St. John Ambulance
- Indian Red Cross Society
- Healthcare for the Underprivileged, Scheduled Castes and Scheduled Tribes
- Medical Care for Remote & Marginalised Tribal & Nomadic Communities
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary Key Data Projections, 2009-2014
- Summary of the Indian Pharmaceutical Market, 2009
- Market Projections, 2009-2014
- SWOT Analysis of the Indian Pharmaceutical Market
- Espicom Analysis of the Indian Pharmaceutical Market, 2009
- Pharmaceutical Import Summary, 2003-2007 (US$000s)
- Leading Suppliers, 2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007
- Leading Suppliers of Finished Medicaments, 2007
- Imports of Pharmaceuticals, 2003-2007 (US$000s)
- Pharmaceutical Import Trends
- Leading Suppliers, 2007 (US$000s)
- Leading Suppliers by Category, 2007 (US$000s)
- Alembic: Manufacturing Facilities
- Alembic: FDA ANDA Approvals, 2009
- Alembic: Financial Results 2005-2009
- Aurobindo Pharma: Manufacturing Facilities
- Aurobindo Pharma: ANDA Approvals, 2007-2009
- Cephazone Pharma: FDA ANDA Approval, 2007
- Aurobindo Pharma: Financial Results, 2005-2009
- Biocon: Financial Results, 2005-2009
- Cipla: Manufacturing Facilities
- Cipla: FDA ANDA Approvals, 2007-2009
- Cipla: Tentative FDA ANDA Approvals
- Cipla: Tentative FDA NDA Approvals
- Cipla: Financial Results, 2005-2009
- Claris Lifesciences: FDA ANDA Approvals, 2008
- Dr. Reddy's: Manufacturing Facilities
- Dr. Reddy's: FDA ANDA Approvals, 2007-2009
- Dr. Reddy's: Financial Summary, 2005-2009
- Glenmark: Manufacturing Facilities
- Glenmark: FDA ANDA Approvals, 2007-2009
- Glenmark: Financial Results, 2005-2009
- Jubilant Organosys: FDA ANDA Approvals, 2004-2009
- Jubilant Organosys: Financial Results, 2005-2009
- Lupin: Manufacturing Facilities
- Lupin: FDA ANDA Approvals 2007-2009
- Lupin: Tentative FDA Approvals
- Lupin: Financial Results, 2005-2009
- Matrix: Manufacturing Facilities
- Matrix: FDA ANDA Approvals, 2008-2009
- Matrix: Tentative ANDA Approvals
- Matrix: Financial Results, 2004-2008
- Natco Pharma Financial Results, 2003-2007
- Orchid: Manufacturing Facilities
- Orchid's Top-10 Brands
- Orchid: FDA ANDA Approvals, 2007-2009
- Orchid: Financial Results, 2005-2009
- Piramal Healthcare: Manufacturing Facilities
- Piramal Healthcare: Financial Results, 2005-2009
- Ranbaxy: Manufacturing Facilities
- Ranbaxy Laboratories: FDA ANDA Approvals, 2007-2009
- Ohm Laboratories: FDA ANDA Approvals, 2006-2008
- Ranbaxy: Financial Results, 2004-2008
- Akorn Strides: FDA ANDA Approvals, 2007-2009
- Sagent Strides: FDA ANDA Approvals
- Strides: Financial Results, 2005-2008
- Sun Pharma: Manufacturing Facilities
- Sun Pharma: FDA ANDA Approvals, 2007-2009
- Caraco Pharmaceutical: ANDA Approvals, 2007-2008
- Sun Pharma: Financial Results, 2005-2009
- Torrent Pharma: FDA ANDA Approvals, 2007-2009
- Torrent Pharma: Financial Results, 2004-2008
- Wockhardt Manufacturing Facilities
- Wockhardt: FDA ANDA Approvals, 2007-2009
- Wockhardt: Financial Results, 2004-2008
- Zydus Cadila: Manufacturing Facilities
- Zydus: ANDA Approvals, 2007-2009
- Zydus Cadila: Financial Results, 2004-2008
- Pharmaceutical Export Summary, 2003-2007 (US$000s)
- Exports of Pharmaceuticals, 2003-2007 (US$000s)
- Pharmaceutical Export Trends
- Pharmaceutical Exports by Destination, 2007 (US$000s)
- Balance of Trade in Pharmaceuticals, 2003-2007 (US$000s)
- Summary of Demographic Data
- Projected Population, 2009-2014
- Reported Incidence of Vaccine Preventable Diseases, 2006
- Reported Malaria Incidence & Deaths, 2006
- Reported Kala-azar Cases & Deaths, 2006
- Suspected Japanese Encephalitis Cases & Deaths, 2006
- Healthcare Expenditure, 2008
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds, 2002
- Hospital Bed Projections, 2009-2014
- Beds in Selected Hospitals, 2007
- AIIMS Hospital Activity, 2005/06
- Projected Number of Physicians, 2009-2014
List of Charts
- Pharmaceutical Imports, Exports & Balance of Trade, 1998-2007 (US$000s)
- Pharmaceutical Imports by Type, 2007 (%)
- Percentage Change in Imports by Type, 2003-2007
- Leading Pharmaceutical Suppliers, 2007 (%)
- Percentage Change in Exports by Type, 2003-2007
- Pharmaceutical Exports by Destination, 2007 (%)
- Population by Age Group, 2006 (%)
- Medically Certified Deaths by Cause, 2000
- Health Expenditure by Source, 2001/02 (%)
PAKISTAN
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Local Manufacturers
- CCL
- Cyanamid (Pakistan) Ltd., Wyeth Lederle Division
- Efroze
- Epla Labs
- Highnoon Laboratories Ltd.
- Kobec Pharmacals
- Dr Raza Pharma Ltd.
- ZAFA Pharmaceutical Laboratories (Private) Ltd.
- Multinational Manufacturers
- Sanofi-Aventis Ltd.
- GlaxoSmithKline Pakistan Ltd.
- Reckitt Benckiser Pakistan
- Searle Pakistan Ltd.
- Biotechnology
- Pakistan's First Biotech Manufacturing Plant
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- Pharmaceutical Registration
- Licensing
- Retail Licences
- Manufacturing Licences
- Labelling & Packaging
- Labelling & Packaging Dispute
- Post-Marketing Surveillance
- Advertising
- Pricing & Reimbursement
- Pricing Development
- Sales Tax Confusion
- Medicine Tariffs Abolished
- Prices of 240 Drugs Increased by up to 20%
- Intellectual Property
- Patent Protection & Intellectual Property Rights
- Background to Current Situation
- Counterfeit Pharmaceuticals
- Counterfeit Drugs Account for 40-50% of Drugs Available in Pakistan
- Drive Against Spurious Drugs Launched
- Drug Smuggling Estimated at Rs1.5 Billion
- Over 50% of Drugs in the Sindh Region are Reported to be Counterfeit
- Pharmaceutical Distribution
- Wholesaling/Importers
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases & Non-communicable diseases
- HIV/AIDS
- Healthcare System
- Organisation & Administration
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Pakistan Pharmaceutical Market, 2009
- Market Projections, 2009-2014
- SWOT Analysis of the Pakistan Pharmaceutical Market, 2009
- Espicom Analysis of Pakistan's Health Sector
- Imports by Category, 2003-2007 (US$000s)
- Import Trends, 2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Pharmaceutical Manufacturing Plants by Province
- Multinational Manufacturers
- Exports by Category, 2003-2007 (US$000s)
- Export Trends, (US$000s)
- Leading Destinations, 2007 (US$000s)
- Registered Drugs under the 1976 Drugs Act
- Registered Drugs, 1999-2004
- Registration Fees (Rs)
- Drug Manufacturing License (Rs)
- Summary of Demographic Data, 2005-2008
- Projected Population, 2009-2014
- Healthcare Expenditure, 2005-2006
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds, 2008
- Hospital Bed Projections, 2009-2014
- Projected Number of Physicians, 2009-2014
|
 |
